Medical Oncology

, 34:18 | Cite as

Simultaneous PET/MRI assessment of response to cytotoxic and hormone neo-adjuvant chemotherapy in breast cancer: a preliminary report

  • Valeria RomeoEmail author
  • Massimiliano D’Aiuto
  • Giuseppe Frasci
  • Massimo Imbriaco
  • Emanuele Nicolai
Short Communication


The aim of this study was to assess the response to cytotoxic and hormone neo-adjuvant chemotherapy in four patients with locally advanced breast cancer by simultaneous PET/MRI. Four patients with locally advanced breast cancer underwent simultaneous PET/MRI of the breast using a 3 T Biograph mMR before and after neo-adjuvant chemotherapy (two patients were treated with hormone-therapy and two patients were treated with cytotoxic chemotherapy). Morpho-structural tumoral features and tumor size were assessed; area value, metabolic (SUV and MTV) and functional (ADC, K trans, V e, k ep and iAUC) data were obtained by positioning regions of interest. A comparison of all parameters between the pre- and post-treatment PET/MRI examinations and between the two different therapeutic schedules was assessed. In patients treated with cytotoxic chemotherapy and classified as PR, there was a significant reduction of post-treatment morphological, metabolic and functional parameters. In a patient treated with hormone therapy, classified as SD, there was an increase of all post-treatment perfusion parameters, a substantially stable ADC value and a poor reduction of lesion size and of maximum SUV (SUVmax) values; the last patient, treated with hormone therapy and classified as PR, showed a significant reduction of lesion size and SUVmax values with a reduction of perfusion parameters and substantially stable ADC values. Multiparametric evaluation with simultaneous PET/MRI could be a useful tool to assess the response to cytotoxic and hormone neo-adjuvant chemotherapy in patients with breast cancer. Future studies in a larger cohort of patients are warranted to confirm the results of this preliminary study.


Simultaneous PET/MRI Breast cancer Neo-adjuvant chemotherapy 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Rosenkrantz AB, Friedman K, Chandarana H, et al. Current status of hybrid PET/MRI in oncologic imaging. AJR Am J Roentgenol. 2016;206(1):162–72.CrossRefPubMedGoogle Scholar
  2. 2.
    Ho AM, Kalantari BN. PET/MRI: a new frontier in breast cancer imaging. Breast J. 2016;22(3):261–3.CrossRefPubMedGoogle Scholar
  3. 3.
    Tabouret-Viaud C, Botsikas D, Delattre BM, et al. PET/MR in breast cancer. Semin Nucl Med. 2015;45(4):304–21.CrossRefPubMedGoogle Scholar
  4. 4.
    Margolis NE, Moy L, Sigmund EE, et al. Assessment of aggressiveness of breast cancer using simultaneous 18F-FDG-PET and DCE-MRI: preliminary observations. Clin Nucl Med. 2016;41(8):e355–61.CrossRefPubMedGoogle Scholar
  5. 5.
    Eiber M, Martinez-Möller A, Souvatzoglou M, et al. Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions. Eur J Nucl Med Mol Imaging. 2011;38(9):1691–701.CrossRefPubMedGoogle Scholar
  6. 6.
    Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours; Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMedGoogle Scholar
  7. 7.
    O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified Guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280(2):576–84.CrossRefPubMedGoogle Scholar
  8. 8.
    Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med. 1991;17(2):357–67.CrossRefPubMedGoogle Scholar
  9. 9.
    Tateishi Y, Miyake M, Nagaoka T, et al. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging—prospective assessment. Radiology. 2012;263(1):53–63.CrossRefPubMedGoogle Scholar
  10. 10.
    Weber WA, Schwaiger M, Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol. 2000;27(7):683–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Xu QG, Xian JF. Role of quantitative magnetic resonance imaging parameters in the evalution of treatment response in malignant tumors. Chin Med J. 2015;128(8):1128–33.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Yankeelov TE, Lepage M, Chakravarthy A. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer. Magn Reson Imaging. 2007;25(1):1–13.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Advanced Biomedical SciencesUniversity Federico II of NaplesNaplesItaly
  2. 2.Breast DepartmentNational Cancer Institute of Naples IRCCS “G. Pascale”NaplesItaly
  3. 3.IRCCS SDNNaplesItaly

Personalised recommendations